MiNDERA closes $1 million Seed financing round

MiNDERA Corp. ("MiNDERA), a leader in non-invasive molecular diagnostics for dermatology and skin-related cancers, announced today the close of its $1 million Seed financing round. Scientific Health Development and other individual investors are among MiNDERA's new investors. This financing round will enable MINDERA to further validate its proprietary micro-needle technology and prepare for the launch of its first research products.

"We are very pleased to welcome Scientific Health Development ("SHD") among our investors. Our Seed round is now oversubscribed, which is a significant milestone for the company. We believe this is a recognition of the quality of our science, validation of our technology and its potential to fundamentally change the way skin diseases are studied and diagnosed," said Philippe Nore, MiNDERA's CEO and co-founder. "The proceeds of the round will be focused on product and development activities. We are looking forward to generating and publishing compelling data in the near future".

Andrew Offer, Managing Director at Scientific Health Development will be joining MiNDERA's Board of Directors following SHD's investment in the company. "We are very excited for the many potential applications of the MiNDERA platform. The ability to non-invasively extract molecular information from the skin lends itself to numerous unique opportunities," Mr. Offer suggested in regards to MiNDERA's technology.